Ocugen, Inc.
OCGNNasdaq
$1.36
↓ -0.7%Jul 17 close · end-of-day
Price
1Y↑ +30.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$445.5M
Enterprise Value
$442.8M
P/E
—
P/S
99.8
P/B
76.7
EV/EBITDA
—
PEG
—
FCF Yield
-13.4%
Dividend Yield
—
Revenue (TTM)
$4.5M
Net Income (TTM)
-$71.8M
Free Cash Flow (TTM)
-$59.6M
Gross Margin
—
Operating Margin
-1483.8%
Net Margin
-1608.7%
ROE
-1237.3%
ROIC
-1689.0%
Debt / Equity
5.0
Net Cash
$2.7M
Return 1Y
+36.0%
Company profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD) and OCU200, is in preclinical development stage.
- CEO
- Shankar Musunuri
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Pennsylvania
- Website
- ocugen.com
Management & directors
- Johnson-Greene Treerita EssalimaChief Financial Officer
- Musunuri ShankarChief Executive Officer
- Ramachandran RameshChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
OCGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.5M↑ +3.5%
Diluted EPS-$0.06↑ +20.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $43,000.00 | $0.00 | $2.5M | $6.0M | $4.1M | $4.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$21.3M | -$58.0M | -$89.1M | -$65.5M | -$54.8M | -$62.9M |
| Net income | -$21.8M | -$58.4M | -$86.8M | -$63.0M | -$54.0M | -$68.0M |
| Diluted EPS | -$0.31 | -$0.30 | -$0.40 | -$0.26 | — | — |
| Operating cash flow | -$14.7M | -$47.9M | -$60.1M | -$62.1M | -$42.1M | -$57.0M |
| Free cash flow | -$15.0M | -$48.9M | -$64.5M | -$72.5M | -$45.5M | -$57.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -49500.0% | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Net margin | -50748.8% | — | -3488.9% | -1043.7% | -1331.7% | -1540.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | $764,000.00 | $1.5M | $1.4M | $1.8M | -$193,000.00 | $1.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.4M | -$13.3M | -$13.8M | -$14.5M | -$13.8M | -$17.6M | -$17.0M | -$17.8M |
| Net income | -$15.3M | -$13.0M | -$13.8M | -$15.3M | -$14.7M | -$20.1M | -$17.9M | -$19.2M |
| Diluted EPS | -$0.04 | — | — | -$0.05 | — | — | — | -$0.06 |
| Operating cash flow | -$9.9M | -$11.3M | -$10.4M | -$19.4M | -$10.7M | -$12.9M | -$14.0M | -$21.8M |
| Free cash flow | -$10.4M | -$11.8M | -$10.4M | -$19.4M | -$10.8M | -$13.0M | -$14.0M | -$21.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1354.0% | -1166.5% | -1811.5% | -979.1% | -1004.7% | -1006.0% | 8805.7% | -1163.7% |
| Net margin | -1339.2% | -1141.7% | -1809.7% | -1036.5% | -1073.5% | -1144.5% | 9253.9% | -1250.9% |
Company news
Jul 11, 2026
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Johnson-Greene Treerita Essalima· Chief Financial Officer | Buy | 21,000 | $1.23 | $25,830.00 | filing |
| 2026-04-01 | Zhang Junge | Option exercise | 66,929 | $1.42 | $95,039.18 | filing |
| 2026-04-01 | Zhang Junge | Option exercise | 112,205 | $0.46 | $51,614.30 | filing |
| 2026-04-01 | Zhang Junge | Option exercise | 15,000 | $0.51 | $7,650.00 | filing |
| 2026-01-02 | Musunuri Shankar· Chief Executive Officer | Award | 3,123,201 | $0.00 | $0.00 | filing |
| 2026-01-02 | Ramachandran Ramesh· Chief Accounting Officer | Award | 207,300 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.